ACAD ACADIA PHARMACEUTICALS INC 5X GAINS COMING SOON (HODL)

many products releasing soon
Sector: Health Technology
Industry: Biotechnology
Employees: 503
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Valuation
Market Capitalization
8.373B
Enterprise Value (MRQ)
5.922B
Enterprise Value/EBITDA (TTM)
—
Total Shares Outstanding (MRQ)
155.861M
Number of Employees
503
Number of Shareholders
26
Price to Earnings Ratio (TTM)
—
Price to Revenue Ratio (TTM)
22.1988
Price to Book (FY)
11.6201
Price to Sales (FY)
22.7131
Balance Sheet
Quick Ratio (MRQ)
7.1997
Current Ratio (MRQ)
7.2630
Debt to Equity Ratio (MRQ)
0.0141
Net Debt (MRQ)
-642.407M
Total Debt (MRQ)
8.999M
Total Assets (MRQ)
747.45M
Operating Metrics
Return on Assets (TTM)
-0.3812
Return on Equity (TTM)
-0.4504
Return on Invested Capital (TTM)
-0.4450
Revenue per Employee (TTM)
674107.3559
Price History
Average Volume (10 day)
1.571M
1-Year Beta
0.7491
52 Week High
58.7200
52 Week Low
21.5600
Dividends
Dividends Paid (FY)
0
Dividends Yield (FY)
0
Dividends per Share (FY)
0
Margins
Net Margin (TTM)
-0.6499
Gross Margin (TTM)
0.9621
Operating Margin (TTM)
-0.6784
Pretax Margin (TTM)
-0.6485
Income Statement
Basic EPS (FY)
-1.5982
Basic EPS (TTM)
-1.5783
EPS Diluted (FY)
-1.5982
Net Income (FY)
-235.259M
EBITDA (TTM)
-245.781M
Gross Profit (MRQ)
86.899M
Gross Profit (FY)
327.732M
Last Year Revenue (FY)
339.076M
Total Revenue (FY)
339.076M
Free Cash Flow (TTM)
-135.258M